阿司匹林加重性呼吸道疾病：药物治疗的最新进展
Aspirin-exacerbated respiratory disease: Update on medical management.
作者信息
White Andrew A, Woessner Katharine, Simon Ronald
机构信息
Scripps Clinic, Division of Allergy, Asthma and Immunology, Scripps Green Hospital, San Diego, CA, USA.
出版信息
World J Otorhinolaryngol Head Neck Surg. 2020 Oct 15;6(4):241-247. doi: 10.1016/j.wjorl.2020.07.009. eCollection 2020 Dec.
Abstract
Aspirin-exacerbated respiratory disease (AERD) is frequently diagnosed in patients with severe type 2 airway inflammation presenting with nasal polyps and severe asthma. It has been associated with a recalcitrant course with high medical and surgical requirements. The advent of recent biological and other targeted treatments show promise in the medical management of patient with AERD. The goal of complete disease control where patients no longer require recurrent surgical procedures, systemic corticosteroid exposure and may live with a stable and relatively normal quality of life is now within reach. Further work is necessary to identify biomarkers predictive of treatment response.
摘要
阿司匹林加重性呼吸系统疾病（AERD）常见于患有严重2型气道炎症、伴有鼻息肉和重度哮喘的患者。它与顽固病程相关，对药物和手术治疗需求较高。近期生物制剂及其他靶向治疗方法的出现为AERD患者的医学管理带来了希望。实现疾病完全控制的目标，即患者不再需要反复进行外科手术、避免全身使用糖皮质激素，并且能够以稳定且相对正常的生活质量生活，如今已触手可及。还需要进一步开展工作以确定预测治疗反应的生物标志物。
相似文献
1
Aspirin-exacerbated respiratory disease: Update on medical management.阿司匹林加重性呼吸道疾病：药物治疗的最新进展
World J Otorhinolaryngol Head Neck Surg. 2020 Oct 15;6(4):241-247. doi: 10.1016/j.wjorl.2020.07.009. eCollection 2020 Dec.
2
Longitudinal progression of aspirin-exacerbated respiratory disease: analysis of a national insurance claims database.阿司匹林加重性呼吸系统疾病的纵向进展：国家保险索赔数据库分析。
Int Forum Allergy Rhinol. 2019 Dec;9(12):1420-1423. doi: 10.1002/alr.22412. Epub 2019 Aug 23.
3
Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature.哮喘患者中阿司匹林加重性呼吸系统疾病的流行情况：文献荟萃分析。
J Allergy Clin Immunol. 2015 Mar;135(3):676-81.e1. doi: 10.1016/j.jaci.2014.08.020. Epub 2014 Oct 3.
4
Cortactin expression in nasal polyps of Aspirin-Exacerbated Respiratory Disease (AERD) patients.阿司匹林加重性呼吸疾病（AERD）患者鼻息肉中皮层肌动蛋白的表达
Am J Otolaryngol. 2018 May-Jun;39(3):293-298. doi: 10.1016/j.amjoto.2018.03.012. Epub 2018 Mar 5.
5
Update on the Management of Aspirin-Exacerbated Respiratory Disease.阿司匹林诱发的呼吸道疾病管理的最新进展
Allergy Asthma Immunol Res. 2016 Jul;8(4):298-304. doi: 10.4168/aair.2016.8.4.298.
6
Aspirin-exacerbated respiratory disease and current treatment modalities.阿司匹林加重性呼吸疾病及当前治疗方式
Eur Arch Otorhinolaryngol. 2017 Mar;274(3):1291-1300. doi: 10.1007/s00405-016-4273-1. Epub 2016 Aug 18.
7
Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis.通过潜在类别分析区分的阿司匹林加重性呼吸系统疾病的某些亚表型。
J Allergy Clin Immunol. 2014 Jan;133(1):98-103.e1-6. doi: 10.1016/j.jaci.2013.07.004. Epub 2013 Aug 27.
8
Aspirin or other nonsteroidal inflammatory agent exacerbated asthma.阿司匹林或其他非甾体类抗炎药可加重哮喘。
J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):653-7. doi: 10.1016/j.jaip.2014.09.009. Epub 2014 Nov 6.
9
Survey-Defined Patient Experiences With Aspirin-Exacerbated Respiratory Disease.调查定义的阿司匹林加重性呼吸系统疾病患者体验。
J Allergy Clin Immunol Pract. 2015 Sep-Oct;3(5):711-8. doi: 10.1016/j.jaip.2015.03.001. Epub 2015 Apr 7.
10
An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease.阿司匹林加重的呼吸道疾病的上呼吸道发病机制的最新研究进展。
Curr Opin Allergy Clin Immunol. 2014 Feb;14(1):1-6. doi: 10.1097/ACI.0000000000000021.
引用本文的文献
1
Polyps' Extension and Recurrence in Different Endotypes of Chronic Rhinosinusitis: A Series of 449 Consecutive Patients.不同内镜分型慢性鼻-鼻窦炎中息肉的扩展与复发：449例连续病例系列研究
J Clin Med. 2024 Feb 16;13(4):1125. doi: 10.3390/jcm13041125.
2
Immune endotyping and gene expression profile of patients with chronic rhinosinusitis with nasal polyps in the aspirin-exacerbated respiratory disease (AERD) and the non-AERD subgroups.阿司匹林加重性呼吸道疾病（AERD）和非AERD亚组中伴有鼻息肉的慢性鼻-鼻窦炎患者的免疫分型和基因表达谱。
Allergy Asthma Clin Immunol. 2024 Feb 15;20(1):14. doi: 10.1186/s13223-024-00876-w.
3
Aspirin-exacerbated respiratory disease: Updates in the era of biologics.阿司匹林加重性呼吸系统疾病：生物制剂时代的新进展。
Ann Allergy Asthma Immunol. 2023 Sep;131(3):317-324. doi: 10.1016/j.anai.2023.05.016. Epub 2023 May 22.
4
Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?非甾体抗炎药加重的呼吸道疾病（N-ERD）中的单克隆抗体或阿司匹林脱敏治疗？
Front Allergy. 2023 Apr 12;4:1080951. doi: 10.3389/falgy.2023.1080951. eCollection 2023.
5
Identifying barriers to care for complex airway disease and multidisciplinary solutions to optimize therapy in Canada.识别复杂气道疾病护理的障碍以及加拿大优化治疗的多学科解决方案。
J Otolaryngol Head Neck Surg. 2022 Apr 15;51(1):15. doi: 10.1186/s40463-022-00576-8.
6
Pathomechanisms of AERD-Recent Advances.阿司匹林性呼吸道疾病的发病机制——最新进展
Front Allergy. 2021 Sep 10;2:734733. doi: 10.3389/falgy.2021.734733. eCollection 2021.
7
AERD: Quo Vadis?阿司匹林三联征：何去何从？
World J Otorhinolaryngol Head Neck Surg. 2020 Oct 29;6(4):201-202. doi: 10.1016/j.wjorl.2020.05.011. eCollection 2020 Dec.
本文引用的文献
1
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.度普利尤单抗治疗伴有鼻息肉的重度慢性鼻-鼻窦炎患者的疗效和安全性（LIBERTY NP SINUS-24 和 LIBERTY NP SINUS-52）：两项多中心、随机、双盲、安慰剂对照、平行分组 3 期临床试验的结果。
Lancet. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19.
2
Long-term assessment of aspirin desensitization shows successful bridging with non-aspirin nonsteroidal anti-inflammatory drugs for procedures.长期的阿司匹林脱敏评估显示，在进行手术时，使用非阿司匹林类非甾体抗炎药成功地进行了桥接。
Allergy Asthma Proc. 2019 Sep 1;40(5):311-315. doi: 10.2500/aap.2019.40.4239.
3
Effect of Zileuton Treatment on Sinonasal Quality of Life in Patients with Aspirin-Exacerbated Respiratory Disease.齐留通治疗对阿司匹林加重性呼吸道疾病患者鼻-鼻窦生活质量的影响。
Am J Rhinol Allergy. 2019 Nov;33(6):791-795. doi: 10.1177/1945892419873211. Epub 2019 Sep 4.
4
Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial.阿司匹林加重呼吸病患者中阿司匹林治疗对生物标志物的独特作用：一项前瞻性试验。
Am J Respir Crit Care Med. 2019 Sep 15;200(6):704-711. doi: 10.1164/rccm.201809-1755OC.
5
Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD.度普利尤单抗可改善慢性鼻-鼻窦炎伴鼻息肉和阿司匹林性呼吸道疾病患者的鼻息肉负担并控制哮喘。
J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2462-2465.e1. doi: 10.1016/j.jaip.2019.03.044. Epub 2019 Apr 4.
6
Omalizumab can inhibit respiratory reaction during aspirin desensitization.奥马珠单抗可抑制阿司匹林脱敏过程中的呼吸道反应。
Ann Allergy Asthma Immunol. 2018 Jul;121(1):98-104. doi: 10.1016/j.anai.2018.05.007. Epub 2018 May 16.
7
A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease.美泊利单抗治疗阿司匹林加重的呼吸道疾病患者的回顾性分析
J Allergy Clin Immunol Pract. 2018 May-Jun;6(3):1045-1047. doi: 10.1016/j.jaip.2018.01.038. Epub 2018 Mar 6.
8
Asthma Exacerbations: Pathogenesis, Prevention, and Treatment.哮喘恶化：发病机制、预防和治疗。
J Allergy Clin Immunol Pract. 2017 Jul-Aug;5(4):918-927. doi: 10.1016/j.jaip.2017.05.001.
9
Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial.美泊利珠单抗可减少重度鼻息肉患者的手术需求：一项随机试验。
J Allergy Clin Immunol. 2017 Oct;140(4):1024-1031.e14. doi: 10.1016/j.jaci.2017.05.044. Epub 2017 Jul 4.
10
Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: A single-center study.阿司匹林脱敏治疗阿司匹林加重性呼吸道疾病的安全性和结局：一项单中心研究。
J Allergy Clin Immunol. 2018 Jan;141(1):250-256. doi: 10.1016/j.jaci.2017.05.006. Epub 2017 May 25.
Zotero 插件